News | Antiplatelet and Anticoagulation Therapies | September 01, 2021

One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 

Hot Line session at ESC Congress does not support the use of one month DAPT

One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients undergoing stent implantation. That was the finding of late-breaking research presented in a Hot Line session at European Society of Cardiology (ESC) Congress 2021.[1]

“One-month DAPT and subsequent clopidogrel monotherapy failed to achieve noninferiority for net clinical benefit compared with standard 12-month DAPT after ACS. There was a trend toward an increase in cardiovascular events despite a reduction in major bleeding events," explained study author Dr. Hirotoshi Watanabe of Kyoto University, Japan.

The STOPDAPT-2 trial previously demonstrated that among patients undergoing percutaneous coronary intervention (PCI), one month of DAPT followed by clopidogrel monotherapy resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, compared with 12 months of DAPT with aspirin and clopidogrel.[2] In that trial, 62% of patients had stable coronary artery disease and 38% had ACS.

To generate sufficient statistical power to compare the effect of the two treatments in ACS patients alone, the STOPDAPT-2 ACS trial enrolled 2,988 ACS patients and pooled the results with the 1,148 ACS patients in STOPDAPT-2 – for a total of 4,136 patients. Both trials used the same protocol. Participants were randomly assigned in a 1:1 ratio to one-month DAPT followed by clopidogrel monotherapy or 12-month DAPT after PCI with cobalt-chromium everolimus-eluting stents.

The primary outcome was a composite of cardiovascular and bleeding outcomes at one year: death from cardiovascular causes, myocardial infarction, definite stent thrombosis, ischemic or hemorrhagic stroke, and Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding.

The two major secondary endpoints were: 1) a cardiovascular composite outcome (death from cardiovascular causes, myocardial infarction, definite stent thrombosis, ischemic or hemorrhagic stroke); and 2) TIMI major or minor bleeding.

The primary outcome occurred in 65 patients (3.2% one-year cumulative incidence) assigned to one-month DAPT and 58 patients (2.83%) assigned to 12-month DAPT (hazard ratio [HR] 1.14; 95% confidence interval [CI] 0.80–1.62; p=0.06 for noninferiority).

The major secondary cardiovascular outcome occurred in 56 (2.76%) patients in the one-month DAPT group and 38 (1.86%) patients in the 12-month DAPT group (HR 1.5; 95% CI 0.99–2.26). The major secondary bleeding outcome occurred in 11 (0.54%) patients allocated to one-month DAPT and 24 (1.17%) patients allocated to 12-month DAPT (HR 0.46; 95% CI 0.23-0.94). 

Find more ESC Hot Line late-breaking study news

 

References:

1. STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome. https://www.clinicaltrials.gov/ct2/show/NCT03462498

2. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019;321:2414–2427.
 

Related Content

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart at
The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p